首页|Use of anti tumor necrosis factor-alpha monoclonal antibody for ulcerative jejunoileitis

Use of anti tumor necrosis factor-alpha monoclonal antibody for ulcerative jejunoileitis

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
  • 维普
Ulcerative jejunoileitis is an uncommon clinical syndrome consisting of abdominal pain,weight loss associated with diarrhea,and multiple inflammatory ulcerations and strictures of the small bowel.Ulcerative jejunoileitis can complicate established celiac disease or develop in patients de novo.Increased levels of tumor necrosis factor-alpha (TNF-α) in the small intestine of patients with untreated celiac disease are associated with a role in the immune pathogenesis of this disorder.No specific therapy has been shown to change the course of ulcerative jejunoileitis.We report a case of severe ulcerative jejunoileitis previously unresponsive to traditional therapies,including high dose corticosteroids and cyclosporine.The patient had a dramatic resolution of symptoms and a complete normalization of endoscopic findings after anti-TNF-α monoclonal antibody,infliximab (Remicade(R)).

Ulcerative jejunoileitisBiologic therapyTumor necrosis factor-alphaInfliximab

Gulseren Seven、Adel Assaad、Thomas Biehl、Richard A Kozarek

展开 >

Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA 98101,United States

Department of Pathology, Virginia Mason Medical Center, Seattle, WA 98101, United States

Department of General, Thoracic and Vascular Surgery, Virginia Mason Medical Center, Seattle, WA 98101,United States

2012

10.3748/wjg.v18.i36.5135

世界胃肠病学杂志(英文版)
太原消化病研治中心

世界胃肠病学杂志(英文版)

SCI
影响因子：1.001
ISSN：1007-9327
年,卷(期)：2012.18(36)
  • 2
  • 10